title: Psoriasiform Skin Lesions Are Caused by Both Infliximab and Adalimumab in a Patient with Crohn's Disease.
authors.affiliation: Department of Internal Medicine, Dıskapı Yıldırım Beyazıt Education and Research Hospital, 06080, Altındag, Ankara, Turkey. drcankurtaran88@gmail.com.
authors.forename: Eren
authors.initials: E
authors.lastname: Cankurtaran
authors.affiliation: Department of Gastroenterology, Dıskapı Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey.
authors.forename: Fuat
authors.initials: F
authors.lastname: Ekiz
authors.affiliation: Department of Gastroenterology, Dıskapı Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey.
authors.forename: Mevlut
authors.initials: M
authors.lastname: Hamamci
authors.affiliation: Department of Gastroenterology, Dıskapı Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey.
authors.forename: Hakan
authors.initials: H
authors.lastname: Akinci
authors.affiliation: Department of Gastroenterology, Dıskapı Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey.
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Coskun
authors.affiliation: Department of Gastroenterology, Dıskapı Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey.|Department of Gastroenterology, Yıldırım Beyazıt University School of Medicine, Ankara, Turkey.
authors.forename: Ilhami
authors.initials: I
authors.lastname: Yuksel
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced*
chemical_list: D000893:Anti-Inflammatory Agents; D005765:Gastrointestinal Agents; D000069285:Infliximab; D000068879:Adalimumab